GAO, FDA identify tactics to fight economic adulteration

Manufacturer reluctance to share information about adulterated ingredients hinders the FDA from preventing this form of drug degradation, the agency told the U.S. Government Accountability Office. In addition, the regulator said segregating economic from other forms of adulteration--a distinction currently not made--would help it fight the practice. The GAO finds that the FDA needs better coordination of its many efforts to fight the scourge. GAO report (PDF)

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.